Pancuronium Jelfa (Pancuronium Bromide)

Pancuronium bromide, the active ingredient in Pancuronium Jelfa, is a neuromuscular blocking agent presented as an injectable solution for intravenous use. It facilitates endotracheal intubation, provides muscle relaxation during surgery, and assists with mechanical ventilation in adult patients undergoing operative procedures.

GNH USA supplies Pancuronium Jelfa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Pancuronium bromide is used as a neuromuscular blocking agent to produce skeletal muscle relaxation in specific clinical settings.

- Facilitation of endotracheal intubation: enables rapid, controlled relaxation of the vocal cords and airway muscles for safe tube placement. - Muscle relaxation during surgery: provides profound skeletal muscle paralysis to improve surgical conditions and prevent movement. - Assistance with mechanical ventilation: maintains adequate relaxation for patients requiring prolonged ventilatory support.

Adverse reactions may occur with the use of pancuronium bromide and should be monitored during therapy.

Common Side Effects: - Bradycardia: slowing of heart rate due to vagal stimulation. - Hypertension: transient increase in blood pressure. - Flushing: mild erythema of the skin. - Dry mouth: reduced salivary secretion. - Elevated serum potassium: mild hyperkalaemia.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate intervention. - Prolonged paralysis: extended muscle weakness after discontinuation. - Cardiac arrhythmias: irregular heart rhythms, potentially life‑threatening. - Respiratory depression: inadequate ventilation if dosing is excessive. - Malignant hyperthermia trigger: rare susceptibility in predisposed individuals.

Careful assessment and monitoring are essential when administering pancuronium bromide.

- Cardiac monitoring: observe heart rate and rhythm due to risk of bradycardia and arrhythmias. - Ventilatory support: ensure mechanical ventilation is available throughout the period of paralysis. - Drug interactions: avoid concurrent use with other neuromuscular blockers without dose adjustment. - Pregnancy: category C; use only if potential benefit justifies potential risk to the fetus. - Pediatric use: limit to situations where benefits outweigh risks, with dose individualized. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Pancuronium bromide may interact with other agents that affect neuromuscular transmission or cardiovascular function.

Major Interactions (Avoid): - Aminoglycoside antibiotics: may potentiate neuromuscular blockade. - Magnesium sulfate: enhances muscle relaxation and can lead to prolonged paralysis. - Calcium channel blockers: increase risk of cardiovascular depression.

Moderate Interactions (Monitor Closely): - Inhalational anesthetics: additive effects on muscle relaxation. - Opioids: may deepen respiratory depression when combined. - Beta‑adrenergic antagonists: may exacerbate bradycardia.